EGFR Mutations in Surgically Resected Fresh Specimens from 697 Consecutive Chinese Patients with Non-Small Cell Lung Cancer and Their Relationships with Clinical Features
Yuanyang Lai, Zhipei Zhang, Jianzhong Li, et al.

We aimed to reveal the true status of epidermal growth factor receptor(EGFR) mutations  in  Chinese  patients  with  non-small
cell lung  cancer (NSCLC) after lung resections. EGFR mutations of surgically resected fresh tumor samples from 697 Chinese
NSCLC  patients  were  analyzed  by  Amplification Refractory Mutation System (ARMS). Correlations between EGFR mutation hotspots and clinical features were also explored.

Int. J. Mol. Sci. 2013, 14, 24549-24559; doi:10.3390/ijms141224549

EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases
Dongdong Luo, Xin Ye, Zheng Hu, et al.

Brain metastasis (BM) is a leading cause of death in patients with non-small cell lung cancer (NSCLC). EGFR mutations in primary NSCLC lesions have
been associated with sensitivity to EGFR tyrosine kinase inhibitor (TKI). Therefore, it has become important to understand EGFR mutation status in
BM lesions of NSCLC, and its clinical implications. BM samples of 136 NSCLC patients from South China, in which 15 had paired primary lung tumors, were retrospectively analyzed for EGFR mutation by amplification mutation refractory system (ARMS).

Tumor Biol., 07 November 2013. DOI 10.1007/s 13277-013-1323-9
 

Direct sequencing and amplification refractory mutation system for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
HUILI CHU, CHEN ZHONG, GUOLIANG XUE, et al.

Treatment with epidermal growth factor receptor (EGFR) tyrosine inhibitors (EGFR-TKIs) provides encour-aging  outcomes  for  advanced  non-small  cell  lung  cancer(NSCLC)  patients  with  EGFR  mutations.Pleural effusion is a common complication of NSCLC. We compared direct DNA sequencing and ADx Amplification Refractory Mutation System (ADx-ARMS) to detect EGFR mutations in malignant pleural effusion samples. 

ONCOLOGY REPORTS, DOI:10.3892/or.2013.2709

Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer
Xiao-Hong Han, Ning-Ning Zhang, Li Ma, et al.

Accurate determination of anaplastic lymphoma kinase (ALK) rearrangements is critical in identifying ALK-positive patients for targeted therapy in non-small-cell lung cancer (NSCLC).Fluorescence in situ hybridization(FISH) is the current standard method to detect ALK rearrangements but is technically challenging and costly.

Virchows Arch, 8 August 2013. DOI 10.1007/s00428-013-1472-7

PIK3CA mutation in Chinese patients with lung squamous cell carcinoma
Jinglin Yu, Hua Bai, Zhijie Wang, et al.

To investigate PIK3CA mutation in Chinese patients with lung squamous cell carcinoma (LSCC) and explore their relationship
with clinicopathological profiles.

Chin J Cancer Res, 2013;25(4):416-422

Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma
J. Ying, L. Guo, T. Qiu, et al.

To evaluate the diagnostic value of a novel fully automated immunohistochemistry (IHC) assay for detection of anaplastic
lymphoma kinase (ALK) fusion in a large number of ALK-positive lung adenocarcinoma (ADC) patients.

Annals of Oncology, 24: 2589–2593, 2013